Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8218148 | 1.00 | DPP4 (0.40) | DPP4DPP8DPP9DPP7ATM | |
| SCHEMBL5506106 | 0.88 | — | — | |
| SCHEMBL22622819 | 0.85 | ATM (0.44) | DPP4DPP8ATMALDH1A1 | |
| SCHEMBL529684 | 0.82 | ALDH1A1 (0.34) | ATMALDH1A1 | |
| SCHEMBL3811874 | 0.82 | ALDH1A1 (0.34) | ATMALDH1A1 | |
| SCHEMBL14589116 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL6154069 | 0.80 | ALDH1A1 (0.33) | DPP4DPP8ATMALDH1A1 | |
| Hydrochloric Acid SCHEMBL6154072 | 0.80 | ALDH1A1 (0.33) | DPP4DPP8ATMALDH1A1 | |
| SCHEMBL12548838 | 0.79 | DPP4 (0.38) | DPP4DPP8DPP9DPP7ATM | |
| SCHEMBL5949432 | 0.79 | DPP4 (0.38) | DPP4DPP8DPP9DPP7ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242908-A2 | NOVEL COMPOUNDS | GENOME THERAPEUTICS LTD (GB) | 2025-11-27 | — | — | WO | disclosed |
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-0888351-B1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | THOMAE GMBH DR K (DE) | 2003-10-15 | — | — | EP | disclosed |
| CN-1064362-C | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 2001-04-11 | — | — | CN | disclosed |
| CN-1212694-A | Pyrimido [5,4-D] pyrimidines, medicaments containing these compounds, their use and process for their production | THOMAE GMBH DR K (DE) | 1999-03-31 | — | — | CN | disclosed |
| EP-0888351-A1 | PYRIMIDO 5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | Dr. Karl Thomae GmbH (DE) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997032880-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | DPP4 1438/4885DPP8 3075/4885DPP9 2517/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | DPP4 1438/4885DPP8 3075/4885DPP9 2517/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | DPP4 1438/4885DPP8 3075/4885DPP9 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.